ArticleFrontiers in medicine2020
Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients.
Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 60 citations in OpenAlex.
- Role of the QuantiFERON-Monitor in Assessing the Immune Status of Patients with Acute Respiratory Failure in Adult Intensive Care Units: A Prospective, Observational Study.Annals of laboratory medicine · 2025Observational
- Bronchoalveolar lavage single-cell transcriptomics reveals immune dysregulations driving COVID-19 severity.PloS one · 2025Article
- Associations Between Inflammatory and Catecholamine Markers and Clinical Outcomes in People with Post-Acute SARS-CoV-2 Infection.International journal of general medicine · 2025Article
- Longitudinal single cell atlas identifies complex temporal relationship between type I interferon response and COVID-19 severity.Nature communications · 2024Article
- The detectable anti-interferon-γ autoantibodies in COVID-19 patients may be associated with disease severity.Virology journal · 2023Article
- Case Report: Intercurrent infections in COVID-19-induced sustained immunodepression: is interferon gamma a suitable drug?Frontiers in immunology · 2023Article
- Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study.Frontiers in immunology · 2023Article
- Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients.iScience · 2022Article
- NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients.Cell biochemistry and function · 2022Review
- Observational
- Mature neutrophils and a NF-κB-to-IFN transition determine the unifying disease recovery dynamics in COVID-19.Cell reports. Medicine · 2022Article
- Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing.Biomolecules · 2022Article
- Identification of DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen.Nature communications · 2022Article
- Rhesus negative males have an enhanced IFNγ-mediated immune response to influenza A virus.Genes and immunity · 2022Article
- SARS-CoV-2 NSP13 helicase suppresses interferon signaling by perturbing JAK1 phosphorylation of STAT1.Cell & bioscience · 2022Article
- Article
- Cytokine producing ability of peripheral blood cells from COVID-19 patients after unspecific in vitro stimulation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Article
- SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities.Cytokine & growth factor reviews · 2022Review
- The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections.Frontiers in immunology · 2022Review
- Coinfection of fungi with SARS-CoV-2 is a detrimental health risk for COVID-19 patients.Beni-Suef University journal of basic and applied sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged in Wuhan in December 2019 and has since spread across the world. Even though the majority of patients remain completely asymptomatic, some develop severe systemic complications. In this prospective study we compared the immunological profile of 101 COVID-19 patients with either mild, moderate or severe form of the disease according to the WHO classification, as well as of 50 healthy subjects, in order to identify functional immune factors independently associated with severe forms of COVID-19. Plasma cytokine levels, and cytokine levels upon
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.